OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT
نویسندگان
چکیده
منابع مشابه
Intravitreal Dexamethasone Implant (Ozurdex) in Coats’ Disease
We injected an intravitreal dexamethasone implant in two eyes of 2 pediatric patients with Coats' disease in addition to other treatment modalities, such as intravitreal ranibizumab injection and indirect laser photocoagulation. In both eyes, intraocular pressure moderately rose in a temporary fashion. The dexamethasone implant seems to be a valuable addition to the armamentarium of treatment o...
متن کاملPharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.
PURPOSE To determine the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.). METHODS Thirty-four male monkeys (Macaca fascicularis) received bilateral 0.7-mg DEX implants. Blood, vitreous humor, and retina samples were collected at predetermined intervals up to 270 days after administration. DEX was quantified by liq...
متن کاملA New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®)
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has not been reported in the literature before.
متن کاملAcute retinal necrosis following intravitreal dexamethasone (Ozurdex®) implant.
A 52-year-old woman undergoing azathioprine treatment for rheumatoid arthritis developed acute retinal necrosis a month after intravitreal dexamethasone (Ozurdex ®) implantation for posterior uveitis in the left eye. Varicella zoster virus (VZV) DNA was detected in the anterior chamber and vitreous samples on polymerase chain reaction (PCR) analysis. Retinal detachment occurred despite systemic...
متن کاملPharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
PURPOSE To evaluate dexamethasone pharmacokinetics after implantation of a sustained-release dexamethasone (DEX) intravitreal implant in nonvitrectomized and vitrectomized eyes. METHODS The right eyes of 25 rabbits underwent vitrectomy; contralateral eyes served as nonvitrectomy controls. The 0.7-mg DEX implant was injected into both eyes, and drug concentrations were determined in the vitreo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Retina
سال: 2017
ISSN: 0275-004X
DOI: 10.1097/iae.0000000000001364